Cancer's genetic basis underpins the burgeoning field of personalized oncology.  Advances in high-throughput sequencing technologies have revolutionized our understanding of the somatic mutations driving tumorigenesis, revealing diverse driver genes and pathways specific to individual cancers. This knowledge fuels the development of targeted therapies, moving away from cytotoxic chemotherapy's broad-spectrum approach.  For example, identifying EGFR mutations in lung adenocarcinoma allows for the precise application of tyrosine kinase inhibitors like gefitinib, providing significantly improved outcomes for a subset of patients while minimizing adverse effects.

Furthermore, the identification of tumor mutational burden (TMB) allows for the prediction of response to immunotherapy, particularly checkpoint inhibitors.  High TMB indicates a greater likelihood of immune recognition and subsequent tumor regression.  Beyond individual gene mutations, analysis of epigenetic modifications and genomic instability contributes to a more comprehensive understanding of tumor heterogeneity and progression.  Challenges remain, including the identification of actionable mutations in many cancers and the cost-effectiveness of comprehensive genomic profiling. Nonetheless, the integration of genomic data into clinical practice is accelerating, paving the way for truly personalized cancer treatment strategies tailored to individual patient profiles and their evolving tumor landscapes.